四川天道制药

Sichuan Tiandao Pharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical Group, is a leading global manufacturer of heparin-based anticoagulants. The company specializes in the production of enoxaparin sodium, a low-molecular-weight heparin used to prevent and treat deep vein thrombosis and pulmonary embolism. Tiandao was the first Chinese pharmaceutical company to receive European Union marketing authorization for a biosimilar enoxaparin sodium injection, marketed under brand names such as Inhixa. With large-scale GMP-compliant manufacturing facilities in Chengdu, the company supplies critical cardiovascular and anti-thrombotic medications to international markets including Europe and South America. The company maintains a strong focus on quality control and vertical integration within the heparin supply chain.